Syros Pharmaceuticals is hoping to become the state’s seventh biotech to go public next week, while another company that makes biomaterials to stop bleeding has entered the queue as well.
Cambridge-based Syros has proposed to sell 4 million shares for between $14 and $16 each in its most recent filing. At the midpoint, that would total a $60 million public offering, and Renaissance Capital, a manager of IPO-based funds, reported today that its intention is to hold the IPO sometime next week.
